Other safety measures
diarrhoea, headache
THROMBOPHLEBITIS, HYPERTENSION, DIABETIC FOOT ULCER
During the treatment periods, 52 AEs were reported for icodec (10.9 AEs per participant-year of exposure) and 33 AEs were reported for glargine U100 (21.3 AEs per participant-year of exposure). All AEs were mild or moderate, and the majority were assessed by the investigator as being unlikely related to trial product. The most frequently reported AEs were headache, thrombophlebitis, diarrhoea and hypertension. There were no serious AEs or AEs leading to withdrawal. All AEs were recovered at the end of the trial, except for an AE of diabetic foot ulcer, which was assessed as being unlikely related to the trial product.There were no clinically significant observations for vital signs, electrocardiograms, physical examinations, haematology and biochemistry analyses.